AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 101 min read$DOCS

Sitaram Siddharth sold $50K of DOCS

Sitaram Siddharth (Interim PAO) sold 2,444 shares of Doximity, Inc. (DOCS) at $20.41 on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sitaram Siddharth
Published Jun 10, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

The disclosure confirms an officer’s scheduled open-market sale of DOCS shares; absent additional context, it is usually not a fundamental catalyst.

02

Market read

Confirms modest insider selling in DOCS under a 10b5-1 plan; likely limited trading impact.

03

What to watch

Traders may ignore that the sale date (2026-06-08) precedes the filing; any price reaction would be more likely tied to other contemporaneous news than this Form 4.

Relevance 2/10Novelty 8/10Timing: filed 2026-06-10 (sale dated 2026-06-08)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Doximity, Inc.

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Insider Form 4 shows Doximity officer Sitaram Siddharth sold 2,444 shares in an open-market transaction on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan and the disclosed size is modest versus typical liquidity.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Doximity, Inc.

    DOCS, the company whose insider transaction is disclosed.

  • insider
    Sitaram Siddharth

    Interim PAO who sold 2,444 shares under a 10b5-1 plan.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that reduces interpretability of insider intent.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DOCS insider trading history →

Related articles

SEP 14
MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

finance.yahoo.com2 min
SEP 8
$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

investing.com1 min
AUG 16
$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

aol.com6 min
AUG 14
$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.

fool.com7 min
AUG 11
$DOCSMed

Doximity Stock Surges in Overnight Trading as Chief Executive Highlights High-Margin AI Tool

Doximity (DOCS) shares jumped in overnight trading after CEO Jeffrey Tangney said the company’s new AI search tool generates over 10 times the revenue versus its operating cost. The stock later closed up 33% on Friday. Doximity reported Q1 revenue of $156.6M and adjusted EBITDA of $74.8M, and raised full-year guidance to $671M-$681M. Wells Fargo later downgraded to underweight.

tikr.com6 min